JP2015511618A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511618A5
JP2015511618A5 JP2015502351A JP2015502351A JP2015511618A5 JP 2015511618 A5 JP2015511618 A5 JP 2015511618A5 JP 2015502351 A JP2015502351 A JP 2015502351A JP 2015502351 A JP2015502351 A JP 2015502351A JP 2015511618 A5 JP2015511618 A5 JP 2015511618A5
Authority
JP
Japan
Prior art keywords
vesicle
preparation
use according
surfactant
sulfolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511618A (ja
Filing date
Publication date
Priority claimed from GBGB1205642.0A external-priority patent/GB201205642D0/en
Application filed filed Critical
Publication of JP2015511618A publication Critical patent/JP2015511618A/ja
Publication of JP2015511618A5 publication Critical patent/JP2015511618A5/ja
Pending legal-status Critical Current

Links

JP2015502351A 2012-03-29 2013-03-28 小胞製剤 Pending JP2015511618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
GB1205642.0 2012-03-29
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations

Publications (2)

Publication Number Publication Date
JP2015511618A JP2015511618A (ja) 2015-04-20
JP2015511618A5 true JP2015511618A5 (enExample) 2016-05-26

Family

ID=46159988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502351A Pending JP2015511618A (ja) 2012-03-29 2013-03-28 小胞製剤

Country Status (19)

Country Link
US (1) US9555051B2 (enExample)
EP (1) EP2830630A1 (enExample)
JP (1) JP2015511618A (enExample)
KR (1) KR20150004798A (enExample)
CN (1) CN104349782A (enExample)
AU (1) AU2013241701A1 (enExample)
BR (1) BR112014024033A8 (enExample)
CA (1) CA2867749A1 (enExample)
CL (1) CL2014002547A1 (enExample)
CO (1) CO7121334A2 (enExample)
EA (1) EA038899B1 (enExample)
GB (2) GB201205642D0 (enExample)
IL (1) IL234747A0 (enExample)
IN (1) IN2014DN07913A (enExample)
MX (1) MX2014011516A (enExample)
NZ (1) NZ700472A (enExample)
PH (1) PH12014502065A1 (enExample)
SG (1) SG11201406144TA (enExample)
WO (1) WO2013144289A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178502A1 (en) 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
CA2971642A1 (en) * 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
HRP20210903T1 (hr) 2015-06-30 2021-09-17 Sequessome Technology Holdings Limited Miješane formulacije
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. METHOD OF ADMINISTRATION AND TREATMENT
WO2022180199A1 (en) * 2021-02-25 2022-09-01 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
WO1994001089A1 (de) 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
ES2169566T3 (es) * 1997-11-19 2002-07-01 Schering Ag Composicion con acido azelaico.
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2345355A1 (en) 1998-09-01 2000-03-09 Idea Ag Electrically controlled transport of charged penetrants across barriers
ATE272391T1 (de) 1998-12-23 2004-08-15 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
DK1272161T3 (da) 2000-04-12 2008-05-19 Liplasome Pharma As Lipid-baserede system til afgivelse af lægemidler mod parasitiske infektioner
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
CA2448627A1 (en) 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
WO2003000190A2 (en) 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
CA2476859C (en) 2002-03-13 2011-09-20 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP2006505619A (ja) 2002-10-11 2006-02-16 アイディーイーエー アーゲー 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US20070160656A1 (en) 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
EP1658086A2 (en) 2003-07-21 2006-05-24 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
JP2005179313A (ja) * 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
EP1933856A4 (en) 2005-08-29 2008-11-19 Sepsicure L L C METHOD OF TREATING OR PREVENTING CONDITIONS INDUCED BY GRAM POSITIVE BACTERIA
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
JP5660561B2 (ja) 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
BRPI0924302A2 (pt) 2009-02-05 2019-09-24 Targeted Delivery Tech Limited métodos de reduzir a proliferação e a viabilidade de agentes microbianos
SG176297A1 (en) 2009-06-03 2012-01-30 John Charles Mayo Formulations for the treatment of deep tissue pain
SG178502A1 (en) 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US20160193147A1 (en) 2013-07-31 2016-07-07 Sequessome Technology Holdings Limited Vesicles

Similar Documents

Publication Publication Date Title
JP2017105763A5 (enExample)
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
WO2013114371A8 (en) Dry powder formulations of dnase i
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2015184127A3 (en) Stable cannabinoid formulations
JP2015511618A5 (enExample)
WO2017091739A8 (en) Topical film-forming spray
NZ631100A (en) Soft chewable pharmaceutical products
JP2012255026A5 (enExample)
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2012083138A3 (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
PH12020550864A1 (en) Vesicles for delayed delivery of fragrance their preparation and use thereof
MX350224B (es) Formulaciones parasiticidas transdermicas.
JP2015521599A5 (enExample)
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
HK1221412A1 (zh) 囊泡
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
NZ719321A (en) Storage stable lyophilized tripeptide formulations
JP2016538288A5 (enExample)
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.